Transdermal fentanyl matrix patches Matrifen® and Durogesic® DTrans® are bioequivalent

被引:10
作者
Kress, Hans G. [2 ]
Boss, Hildegard
Delvin, Thomas [4 ]
Lahu, Gezim
Lophaven, Soren [4 ]
Marx, Michael [3 ]
Skorjanec, Sophie
Wagner, Thomas [1 ]
机构
[1] Nycomed GmbH, Dept Pharmacometr, D-78467 Constance, Germany
[2] Med Univ AKH, Dept Special Anaesthesia & Pain Therapy, Vienna, Austria
[3] MEDA Mfg GmbH, ClinPharmCologne, Cologne, Germany
[4] Nycomed Grp, Roskilde, Denmark
关键词
Bioequivalence; Fentanyl; Healthy subjects; Pharmacokinetics; Phase I; Pain; Opioid; Safety; Matrifen (R); Durogesic (R); DTrans (R); AVAILABLE RESERVOIR FORMULATION; CHRONIC NONCANCER PAIN; RELEASE ORAL MORPHINE; CANCER PAIN; DELIVERY-SYSTEM; EFFICACY; SAFETY; ADULTS;
D O I
10.1016/j.ejpb.2010.02.005
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Aim: The pharmacokinetic profiles of the two commercially available transdermal fentanyl patches Matrifen (R) (100 mu g/h) and Durogesic (R) DTrans (R) (100 mu g/h), used to manage severe chronic pain, were compared regarding their systemic exposure, rate of absorption, and safety. Methods: Transdermal matrix fentanyl patches [Matrifen (R) or Durogesic (R) DTrans (R) (100 mu g/h)] were applied for 72 h to 30 healthy male subjects in a randomized, four-period (two replicated treatment sequences), crossover study; 28 subjects completed the study. The pharmacokinetic parameters of fentanyl were determined for 144 h after application using plasma samples. Safety of the patches (adverse events) and performance (adhesion, skin irritation, residual fentanyl content in the patch) were evaluated. Results: The plasma concentration-time curves of Matrifen (R) (Test) and Durogesic (R) DTrans (R) (Reference) were similar. The geometric least square means of the Test/Reference ratio (90% confidence intervals [CI]) were within the range of 80-125%, demonstrating bioequivalence of Matrifen (R) and Durogesic (R) DTrans (R): AUC(0-tlast) 92.5 (CI 88.7-96.4), AUC(0-inf) 91.7 (CI 88.0-95.7), and C-max 98.3 (CI 92.9-104.1). After 72 h application. Matrifen had a more efficient utilization of fentanyl (mean +/- SD 82.3 +/- 9.43%) than Durogesic (R) DTrans (R) (52.3 +/- 12.8%), with substantially lower residual fentanyl in patch after use. The pharmacokinetic parameters showed lower intra- and inter-subject variability for Matrifen than for Durogesic (R) DTrans (R) patch. Conclusions: Despite different technologies, the transdermal fentanyl patches Matrifen (R) and Durogesic (R) DTrans (R) are bioequivalent. Compared with Durogesic (R) DTrans (R), the Matrifen (R) patch had lower initial and lower residual fentanyl content, as well as lower intra- and inter-subject variability, allowing reproducible drug delivery and reliable analgesia. (C) 2010 Elsevier B.V. All rights reserved.
引用
收藏
页码:225 / 231
页数:7
相关论文
共 22 条
  • [1] Transdermal fentanyl versus sustained-release oral morphine in cancer pain: Preference, efficacy, and quality of life
    Ahmedzai, S
    Brooks, D
    [J]. JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 1997, 13 (05) : 254 - 261
  • [2] [Anonymous], 2003, TRANSDERMAL TOPICAL
  • [3] [Anonymous], 2001, GUID IND STAT APPR E
  • [4] Efficacy and safety of transdermal fentanyl and sustained-release oral morphine in patients with cancer and chronic non-cancer pain
    Clark, AJ
    Ahmedzai, SH
    Allan, LG
    Camacho, F
    Horbay, GLA
    Richarz, U
    Simpson, K
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2004, 20 (09) : 1419 - 1428
  • [5] Control of pain in adults with cancer: summary of SIGN guidelines
    Cormie, P. J.
    Nairn, M.
    Welsh, J.
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2008, 337 : 1106 - 1109
  • [6] Opioids in renal failure and dialysis patients
    Dean, M
    [J]. JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2004, 28 (05) : 497 - 504
  • [7] *FDA, 2006, DRAFT GUID LID PATCH
  • [8] *FDA, 2007, INF HEALTHC PROF FEN
  • [9] Transdermal Matrix Fentanyl Membrane Patch (Matrifen®) In Severe Cancer-Related Chronic Pain
    Hair, Philip I.
    Keating, Gillian M.
    McKeage, Kate
    [J]. DRUGS, 2008, 68 (14) : 2001 - 2009
  • [10] Fentanyl transdermal matrix patch (Durotep® MT Patch; Durogesic® DTrans®; Duragesic® SMAT) -: In adults with cancer-related pain
    Hoy, Sheridan M.
    Keating, Gillian M.
    [J]. DRUGS, 2008, 68 (12) : 1711 - 1721